NEO GENOMICS

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



KRAS (G12C) Mutation Analysis for NSCLC

Alternative Name
Biomarker Assist™ KRAS G12C Single Gene Test Program (SGT), KRAS Sponsored Testing Program

Methodology
Molecular

Test Description
Bi-directional sequencing of exons 2, 3, and 4 of the *KRAS* (includes G12C mutation) gene including codons 12, 13, 59, 61, 117, and 146. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12 and 13.

This test is only available through the Amgen-sponsored Biomarker AssistTM *KRAS G12C* Single Gene Test Program for patients with stage IV non-small cell lung carcinoma (NSCLC). A separate test request form is required. Please visit the Test Program webpage for more information and to download the *KRAS G12C* Single Gene Test Request Form.

To order additional testing outside the *KRAS G12C* Single Gene Test Program on the same specimen, please send the tissue block rather than cut slides and submit the NeoGenomics Test Request concurrently with the *KRAS* Test Request Form.

Clinical Significance
The *KRAS G12C* mutation is the most prevalent oncogenic driver in NSCLC, detected in approximately 13% of patients. Tumors with the *KRAS* G12C mutation may respond to targeted therapy such as sotorasib.

Specimen Requirements
- **FFPE solid tumor tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage & Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
Inquire for testing program details.

New York Approved
Yes

Level of Service
Global

Turnaround Time
7 days

References

1. Pakkala S, et al. *JCI Insight.* 2018;3 e120858.
2. Nassar AH, Adib E, Kwiatkowski DJ. *N Engl J Med.* 2021;384:185-187. doi: 10.1056/NEJMc2030638.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

© 2023 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2023 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 032223